Loading...
Loading...
CNSP| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.9K |
| Gross Profit | -0.9K |
| Operating Expense | 4,533.8K |
| Operating I/L | -4,533.8K |
| Other Income/Expense | 11.0K |
| Interest Income | 12.9K |
| Pretax | -4,522.8K |
| Income Tax Expense | 12.9K |
| Net Income/Loss | -4,522.8K |
CNS Pharmaceuticals, Inc. is a clinical pharmaceutical company specializing in the development of anti-cancer drug candidates for brain and central nervous system tumors. Their lead drug candidate, Berubicin, is currently in Phase I and II clinical trials for the treatment of glioblastoma multiforme. The company generates revenue through license agreements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, they have a development agreement with WPD Pharmaceuticals Inc. and a collaboration agreement with Reata Pharmaceuticals, Inc.
